Literature DB >> 24502061

Correlations between the presence of sigmoid interventricular septum and increased relapse risk of stroke in hypertensive patients.

Paloma Manea1, Rodica Ghiuru2.   

Abstract

OBJECTIVES: Comparison between cerebrovascular accident (CVA) relapse in hypertensive patients with sigmoid interventricular septum (SIS) and CVA relapse in hypertensive patients without SIS.
MATERIALS AND METHODS: We selected 36 hypertensive patients, all of them complicated with previous CVA; 18 patients had SIS (Group A) and 18 patients didn't have SIS (Group B). The utilized methods were the following: clinical examination, electrocardiogram, transthoracic echocardiogram, biochemical findings and complete blood count, performed every 3 months, during 2 years of observation. Another method, addressed for CVA relapse patients, were cerebral computed tomography or magnetic resonance imaging .The recommended treatment was administered according to the European therapeutic guidelines.
RESULTS: 6 (out of 18) patients with SIS presented a CVA relapse and only 1 (out of 18) patient without SIS revealed a CVA relapse.
CONCLUSIONS: Our results support recent conclusions from another publications: patients with SIS (an apparently benign condition, which is a part of the cardiac modifications usually discovered in elderly people) have a higher cardiovascular risk for acute events, than the patients without SIS.

Entities:  

Mesh:

Year:  2013        PMID: 24502061

Source DB:  PubMed          Journal:  Rev Med Chir Soc Med Nat Iasi        ISSN: 0048-7848


  1 in total

1.  Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.

Authors:  Takafumi Nakayama; Yoshiko Oshima; Yasuhiro Shintani; Junki Yamamoto; Masashi Yokoi; Tsuyoshi Ito; Kazuaki Wakami; Shuichi Kitada; Toshihiko Goto; Hiroya Hashimoto; Shigeru Kusumoto; Tomonori Sugiura; Shinsuke Iida; Yoshihiro Seo
Journal:  Circ Rep       Date:  2022-03-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.